Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: This paper provides a critical review of the data concerning the effects of combined hormonal contraceptives (CHC) for polycystic ovary syndrome (PCOS). The aim is to determine the best treatment option for each PCOS phenotype. STUDY DESIGN: A literature search of the PubMed database was conducted for randomized clinical trials (RCTs) and observational studies published in any language prior to October 2013. Hyperandrogenism (HA) is the essential diagnostic criterion for PCOS and is frequently associated with insulin resistance (IR) or obesity. The combinations of these criteria define the different PCOS phenotypes and establish the scale of metabolic and cardiovascular risks. RESULTS AND CONCLUSIONS: 19 RCTs and eight observational studies evaluated issues related to the current objectives. CHC represent an effective and safe treatment in women with any PCOS phenotype. In HA/PCOS patients, any CHC analyzed in this review can be used for symptom relief. For patients with metabolic risk, overweight or moderate IR that does not require metformin, a vaginal contraceptive ring appears to be preferred to oral EE/DRP. In these patients, the combination of CHC and myo-inositol may be more effective in controlling endocrine and metabolic profiles. However, further research is needed to define the optimal duration and to clarify the effects of treatment on long-term metabolic outcomes. Future research should also focus on new CHC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Lifestyle changes in women with polycystic ovary syndrome
Lim, S. S., Hutchison, S. K., Van Ryswyk, E., Norman, R. J., Teede, H. J., & Moran, L. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007506.pub4 · Cited by 725
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Moran, L., & Teede, H. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp008 · Cited by 362 · cited 1×
“The combinations of these conditions define the different PCOS phenotypes and establish the scale of metabolic and CVD risk [44,45].”
BackgroundDivergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
Moghetti, P., Tosi, F., Bonin, C., Di Sarra, D., Fiers, T., Kaufman, J.-M., Giagulli, V. A., Signori, C., Zambotti, F., Dall'Alda, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3908 · Cited by 262 · cited 1×
“The combinations of these conditions define the different PCOS phenotypes and establish the scale of metabolic and CVD risk [44,45].”
BackgroundClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
Guastella, E., Longo, R. A., & Carmina, E. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.02.014 · Cited by 205 · cited 1×
“The normoandrogenic PCOS, or type IV, phenotype is relatively uncommon and characterizes patients with normal body mass index (BMI), insulin sensitivity and free androgen index with increased levels of LH and LH/FSH ratio [33,34].”
BackgroundHarris-Glocker, M., Davidson, K., Kochman, L., Guzick, D., & Hoeger, K. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.08.006 · Cited by 66
Fruzzetti, F., Trémollieres, F., & Bitzer, J. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.662547 · Cited by 56
Cited by
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
“Due to these effects it is an effective pharmacological intervention for the treatment of menstrual irregularity, acne, hirsutism, and androgenic alopecia linked to PCOS [68,69].”
BackgroundPoly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Androgens and ovarian function: translation from basic discovery research to clinical impact
Walters, K. A., Rodriguez Paris, V, Aflatounian, A., & Handelsman, D. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0096 · Cited by 104
Amiri, M., Kabir, A., Nahidi, F., Shekofteh, M., & Ramezani Tehrani, F. (2018) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2018.1435779 · Cited by 40
“They concluded that in PCOS patients with HA, any COCs analysed in their review can be used for symptom relief [67].”
Background
Metadata
- Authors
- Mendoza, N., Simoncini, T., & Genazzani, A. D.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2014-09-25
- Volume
- 30
- Issue
- 12
- Pages
- 850-860
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W1990967823
- Cited by
- 38
- References
- 7
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies. https://app.cochat.ai/papers/10.3109/09513590.2014.943725
- The paper
- Mendoza, N., Simoncini, T., & Genazzani, A. D. (2014). Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2014.943725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.